|Bid||3.80 x 200|
|Ask||4.38 x 800|
|Day's Range||4.11 - 4.32|
|52 Week Range||1.13 - 9.87|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sage jumped Tuesday after rival Marinus said it would delay top-line results of a Phase 2 study in postpartum depression.
Shares of biotech Marinus Pharmaceuticals Inc. slid more than 14% in premarket trade Tuesday, after the company reported a wider-than-expected loss for 2017. The company, which is focused on developing ...
Marinus Pharmaceuticals Inc (NASDAQ:MRNS), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
Marinus Pharmaceuticals (MRNS) has initiated a phase two study to test the feasibility of ganaxalone in patients suffering from refractory status epilepticus (or RSE). Data from this study is expected ...
Marinus Pharmaceuticals (MRNS) announced phase two results from its open-label study evaluating the efficacy of ganaxalone in patients suffering from CDKL5 deficiency disorder (or CDD) in September 2017....
Bain Capital unit Bain Capital Life Sciences Investors LLC owns just two names through subsidiaries, Marinus Pharmaceuticals (MRNS) and Dicerna Pharmaceuticals (DRNA). Over the last several days, Bain has cut back on Marinus and bought more shares of Dicerna. From Dec. 15 through 19 Bain sold nearly 1.3 million shares for $10 million, an average of $7.88 each.
Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday — but not on its own merits. The stock moved mostly on sympathy for SAGE ...
Success for Sage Therapeutics' postpartum depression drug bodes well for a related candidate from Marinus Pharmaceuticals.
Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.
Marinus Pharmaceuticals saw its shares make a huge gain to kick off the week after the firm announced top-line results from its mid-stage study in patients with CDKL5 disorder.
The Radnor, Pennsylvania-based company said it had a loss of 21 cents per share. The company's shares closed at $1.87. A year ago, they were trading at $1.67. _____ This story was generated by Automated ...
Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.
On a per-share basis, the Radnor, Pennsylvania-based company said it had a loss of 26 cents. The company's shares closed at $1.44. A year ago, they were trading at $5.49. _____ This story was generated ...